On October 7, 2025, Serina Therapeutics, Inc. announced the drawdown of the first $5 million tranche from a previously announced financing agreement that provides up to $20 million in total funding upon achievement of defined development milestones. The proceeds will be used to advance the company’s planned registrational trial of SER‑252, a POZ‑apomorphine therapy for advanced Parkinson’s disease.
The financing agreement stipulates that subsequent tranches will be released as specific milestones are met, including patient enrollment in the planned Phase 1b registrational study. The initial tranche was received in accordance with the terms of the agreement, and the company has confirmed that it remains on track to initiate the study in the fourth quarter of 2025, with first patient dosing expected before year‑end.
Serina has already filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and received its first Human Research Ethics Committee (HREC) approval in Australia for SER‑252. The registrational study, designated SER‑252‑1b, is a randomized, double‑blind, placebo‑controlled Phase 1b trial that will evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER‑252 versus placebo, with exploratory efficacy measures such as MDS‑UPDRS motor scores.
This funding milestone is significant for investors because it provides the capital necessary to move SER‑252 from IND filing into the critical registrational trial phase, a key step toward potential market approval. The $5 million tranche also demonstrates continued investor confidence and the company’s ability to secure financing for its pipeline, supporting future revenue prospects in the advanced Parkinson’s disease market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.